公开(公告)号：US20240228636A1

公开(公告)日：2024-07-11

申请号：US18481797

申请日：2023-10-05

Applicant: Cellectis ,  Allogene Therapeutics, Inc.

Inventor： Barbara Johnson SASU ,  Arvind RAJPAL ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Julien VALTON

IPC: C07K16/28 ,  A61K35/17 ,  A61K39/00 ,  A61K39/395 ,  C07K14/705 ,  C07K14/725 ,  C07K14/735 ,  C07K16/30 ,  C12N5/00 ,  C12N5/0783 ,  G01N15/01 ,  G01N15/10 ,  G01N15/1031 ,  G01N15/14 ,  G01N15/149

CPC classification number: C07K16/2866 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/001176 ,  A61K39/39558 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70535 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/3061 ,  C12N5/0093 ,  C12N5/0636 ,  C12N5/0638 ,  G01N15/1031 ,  G01N15/14 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/6056 ,  A61K2039/64 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00 ,  G01N2015/016 ,  G01N2015/1006 ,  G01N2015/1028 ,  G01N15/149

Abstract: A polypeptide encoding a chimeric antigen receptor (CAR) comprising at least one extracellular binding domain that comprises a scFv formed by at least a VH chain and a VL chain specific to an antigen, wherein said extracellular binding domain comprises at least one mAb-specific epitope.

公开(公告)号：US20240026376A1

公开(公告)日：2024-01-25

申请号：US18480890

申请日：2023-10-04

Applicant: CELLECTIS

Inventor： Laurent POIROT ,  David SOURDIVE ,  Philippe DUCHATEAU ,  Jean-Pierre CABANIOLS

IPC: C12N15/85 ,  C07K14/74 ,  C12N5/0783 ,  C07K14/705 ,  C12N15/113 ,  C12N15/90

CPC classification number: C12N15/85 ,  C07K14/70539 ,  C12N5/0636 ,  C07K14/70503 ,  C12N15/1138 ,  C12N15/907 ,  C07K2317/24 ,  C07K2317/622

Abstract: The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are characterized in that the expression of beta 2-microglobulin (B2M) and/or class II major histocompatibility complex transactivator (CIITA) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding B2M and/or CIITA, or by using nucleic acid molecules which inhibit the expression of B2M and/or CIITA. In order to further render the T-cell non-alloreactive, at least one gene encoding a component of the T-cell receptor is inactivated, e.g., by using a rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding said TCR component. In addition, expression of immunosuppressive polypeptide can be performed on those modified T-cells in order to prolong the survival of these modified T cells in host organism. Such modified T-cell is particularly suitable for allogeneic transplantations, especially because it reduces both the risk of rejection by the host's immune system and the risk of developing graft versus host disease. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer, infections and auto-immune diseases.

公开(公告)号：US20230416786A1

公开(公告)日：2023-12-28

申请号：US18253977

申请日：2021-11-30

Applicant: CELLECTIS SA

Inventor： Alexandre JUILLERAT ,  Philippe DUCHATEAU ,  Ming YANG

IPC: C12N15/90 ,  C12N9/22 ,  C12N15/86 ,  C07D215/46

CPC classification number: C12N15/907 ,  C12N9/22 ,  C12N15/86 ,  C07D215/46 ,  C12N2750/14143

Abstract: The invention provides aminoquinoline compounds as powerful enhancers of genetic recombination in living cells, especially to perform site-directed gene integration of exogenous DNA template by homologous recombination. In particular, disclosed are methods by which cells are treated with chloroquine and/or hydroxychloroquine prior to, or concomitantly with, the introduction of exogenous DNA templates, and optionally in presence of rare-cutting endonucleases, to obtain higher rates of gene integration or correction.

公开(公告)号：US20230248825A1

公开(公告)日：2023-08-10

申请号：US18005284

申请日：2021-07-23

Applicant: CELLECTIS S.A.

Inventor： Shipra DAS ,  Sumin JO ,  Alexandre JUILLERAT ,  Julien VALTON ,  Laurent POIROT ,  Philippe DUCHATEAU

IPC: A61K39/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90 ,  C12N5/0783 ,  C12N15/113 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K39/4633 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C12N5/0636 ,  A61K39/4611 ,  A61K39/4643 ,  C12N15/1138 ,  A61K39/3955 ,  A61K39/4631 ,  A61P35/00 ,  C12N2800/80 ,  C12N2310/20 ,  C12N2506/11 ,  C12N2501/515 ,  C12N2501/51 ,  C12N2501/2302 ,  A61K2039/5158 ,  C12N2310/531 ,  C12N2310/14

Abstract: The invention relates to therapeutic compositions for allogeneic cellular therapy comprising TCR deficient T-cells, which are genetically engineered to express immune cell engagers, and methods related thereto.

公开(公告)号：US20210139870A1

公开(公告)日：2021-05-13

申请号：US16623171

申请日：2018-06-18

Applicant: CELLECTIS

Inventor： Philippe DUCHATEAU

IPC: C12N9/22 ,  A61K45/06 ,  A61K47/55 ,  A61P31/22

Abstract: The invention pertains to non-viral methods for in vivo delivery of endonuclease reagents compositions to specific tissues or cells. According to the invention, the endonuclease reagents are preferably encapsulated into micelle structures of 50 to 150 nm diameter for intravenous injection, in combination with antiviral compounds. The invention thereby provides therapeutic compositions comprising endonuclease reagents and antiviral compounds for effective elimination of HBV from liver cells and treatment of chronic hepatitis.

公开(公告)号：US20210128613A1

公开(公告)日：2021-05-06

申请号：US16629506

申请日：2018-07-20

Applicant: CELLECTIS

Inventor： Philippe DUCHATEAU ,  Anne-Sophie GAUTRON ,  Laurent POIROT ,  Julien VALTON

IPC: A61K35/17 ,  C12N5/0783 ,  C12N15/113 ,  C07K16/28 ,  A61K39/395

Abstract: The invention pertains to the field of adoptive cell immunotherapy. It provides with engineered immune cells comprising genetic alteration into genes which are involved into immune functions downregulation, especially in response to environment signals such as nutrients depletion. Such method allows the production of more potent immune cells in the context of tumors' microenvironment.

公开(公告)号：US20210017545A1

公开(公告)日：2021-01-21

申请号：US17041359

申请日：2019-03-29

Applicant: CELLECTIS

Inventor： Alex BOYNE ,  Brian BUSSER ,  Philippe DUCHATEAU ,  Aymeric DUCLERT

IPC: C12N15/90 ,  C12N15/86 ,  C07K14/805 ,  C12N15/10 ,  C12N9/22

Abstract: The present invention relates to the field of genome engineering (gene editing). More specifically the invention provides with allele specific TALE-nucleases and methods to operate allele specific gene repair by homologous recombination in primary cells, such as hematopoietic stem cells, blood cells and hepatocytes. These reagents and methods can be used for the genetic treatment of inherited disease, such as sickle cell disease betathalassemia.

公开(公告)号：US20200332004A1

公开(公告)日：2020-10-22

申请号：US16958250

申请日：2018-12-28

Applicant: CELLECTIS

Inventor： Alex BOYNE ,  Laurent POIROT ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT

IPC: C07K16/28 ,  C12N5/0783 ,  C12N15/87 ,  C12N15/86 ,  A61K35/17 ,  A61P35/00

Abstract: A method for engineering less alloreactive immune cells, including T-cells that express chimeric antigen receptors (CARs), using a nucleotide sequence in form of an RNA encoding a anti-TCR CAR to achieve the transient expression of anti-TCR CAR at the cell surface. The transient expression of the anti-TCR CAR recognized by the alpha beta TCR on the cell surface unexpectedly enabled the a purification of the TCR-negative CAR expressing cells. The TCR-negative CAR expressing immune cells can be used in adoptive therapy to treat diseases associated with cell surface antigens, such as cancer with less side effects, in particular less GVHD.

公开(公告)号：US20180237798A1

公开(公告)日：2018-08-23

申请号：US15891496

申请日：2018-02-08

Applicant: Cellectis

Inventor： Philippe DUCHATEAU ,  Andre CHOULIKA ,  Laurent POIROT

IPC: C12N15/85 ,  C12N5/0783 ,  C12N9/22

CPC classification number: C12N15/85 ,  A61K35/17 ,  C12N5/0636 ,  C12N5/0637 ,  C12N5/0638 ,  C12N9/22 ,  C12N15/1138 ,  C12N15/90 ,  C12N2310/20 ,  C12N2510/00 ,  C12Y301/00

Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.

公开(公告)号：US20180237533A1

公开(公告)日：2018-08-23

申请号：US15752195

申请日：2016-08-24

Applicant: CELLECTIS

Inventor： Alexandre JUILLERAT ,  Philippe DUCHATEAU ,  Laurent POIROT

IPC: C07K16/28 ,  A61K31/436 ,  A61K35/17 ,  C07K14/72 ,  A61P35/00

CPC classification number: C07K16/2869 ,  A61K31/436 ,  A61K35/17 ,  A61K38/00 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/721 ,  C07K16/2803 ,  C07K2317/622 ,  C07K2319/03 ,  C12N2510/00

Abstract: The present invention relates to the field of cell immunotherapy and more particularly to a new generation of chimeric antigen receptors (CAR), allowing the control of immune cells endowed with such CARs through the interaction with small molecules. More particularly, the present invention relates to chimeric antigen receptor which comprise in at least one ectodomain a molecular switch turning the antigen binding function of the receptor from an off to on state, and vice versa. The present invention thus provides more controlled and potentially safer engineered CAR endowed immune cells, such as T-lymphocytes.